Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
SAN RAMON, Calif., Feb. 17, 2016 -- SteadyMed Ltd. (Nasdaq:STDY), a pre-NDA stage specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that Jonathan Rigby, President and Chief Executive Officer will present at the RBC Capital Markets 2016 Global Healthcare Conference on Wednesday, February 24, 2016. Mr. Rigby will provide an overview of the company’s business including its lead drug product candidate Trevyent; a combination of the company’s PatchPump and treprostinil for the treatment of Pulmonary Arterial Hypertension (PAH).
Date: Wednesday, February 24, 2016
Time: 1:35 – 2:00 pm ET
Location: New York, NY
A live audio webcast and archive of the presentation will be available through the Events and Presentations page of the company's corporate website (www.steadymed.com).
About SteadyMed
SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent®, a development stage drug product that combines SteadyMed's PatchPump technology with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension (PAH). PatchPump is a proprietary, disposable, parenteral drug administration platform that is prefilled and preprogrammed at the site of manufacture. SteadyMed intends to file an NDA for Trevyent in Q3 2016 and will commercialize Trevyent in the U.S. SteadyMed has licensed certain rights to Cardiome Pharma Corp. for the development and commercialization of Trevyent in Europe, Canada and the Middle East. SteadyMed has offices in San Ramon, California and Rehovot, Israel. For additional information about SteadyMed please visit www.steadymed.com.
CONTACT: Marylyn Rigby Senior Director, Investor Relations and Marketing 925-272-4999 [email protected]
